Conference discusses Public-Private Partnerships in health

Created 19 May 2022
  • PDF
Editor Choice
Share
(0 votes, average 0 out of 5)

‘Public-Private Partnership for sustainable healthcare transformation’ was the main topic of a conference organised by Đầu tư (Investment) newspaper in Hà Nội on May 18.

A panel discussion at the conference on strengthening ‘Public-Private Partnership for sustainable healthcare transformation’ in Hà Nội on May 18. — VNS Photo Thanh Hải

HÀ NỘI — ‘Public-Private Partnership for sustainable healthcare transformation’ was the main topic of a conference organised by Đầu tư (Investment) newspaper in Hà Nội on May 18.

Opening the event, the newspaper's editor-in-chief Lê Trọng Minh said that Việt Nam's health sector faced many challenges, such as increasing infectious and non-communicable diseases, hospital overcrowding, shortage of supplies and equipment, the ageing population as well as the disparity between regions and healthcare levels in terms of quality of medical services and standardisation of modern equipment.

“For the health system to be capable and always ready to respond to future situations, towards a comprehensive and sustainable health care system, it is necessary to have new investment orientations in social resources for the health system, as well as stronger cooperation from the parties involved, including the Public-Private Partnership (PPP) method,” said Minh.

At the event, MPI deputy minister Trần Duy Đông said it was very important to mobilise financial resources for new investments in infrastructure and equipment to improve quality in the health sector and meet people's healthcare needs. In many countries around the world, the application of the PPP model in the health sector has contributed to solving the shortage of capital resources.

“In Việt Nam, the 12th Central Committee’s Resolution No. 19-NQ/TW dated October 25, 2017, emphasised the promotion of PPP investment method in public services, especially health services. The PPP Law, which the National Assembly passed in 2020, has created a stable legal environment for PPP projects and raised confidence for the community of investors and businesses, especially international investors," he said.

However, Đông stressed, that the implementation of the PPP law still faced many shortcomings. PPP projects are implemented mainly in several key areas: transportation, energy, clean water supply, wastewater, and waste treatment. Such projects have not yet been implemented or have not been applied successfully in agriculture, health care, education, culture and sports.

“Although this (health care) is a potential field, it has not yet attracted many investors. From 2019 to now, there have been no more investment projects in the form of PPP in the health sector. Therefore, the conference will be an opportunity to review the policy framework for implementing investment projects in the form of PPP in the medical field. From there, we can identify opportunities and challenges in implementing the PPP model in the health sector,” added Đông.

According to statistics from the World Bank, as of 2019, there were 58 projects on the list of PPP projects in the health sector that were proposed. However, in these projects, only 13 projects have reached the stage of the pre-feasibility study report, six projects have reached the stage of the feasibility study report, five projects have reached the stage of bidding and selecting investors, and two projects remain at their signing stage. PPP projects in the health sector are mostly concentrated in a few cities and provinces, such as Hà Nội, HCM City and Đà Nẵng City.

AstraZeneca Việt Nam chairman and general director Nitin Kapoor said to enhance the health system’s sustainability, and it is needed to uplift the capacity of the grassroots health network and primary healthcare so that non-communicable diseases (NCD) can be managed more proactively and effectively in the community.

“We also need to build a strong domestic pharmaceutical industry to enable Việt Nam to have self-reliance in terms of treatments and solutions, to ensure faster access for local communities,” said Kapoor.

Kapoor also committed to supporting Việt Nam by supplying vaccines and innovative medicines and investing nearly VNĐ600 billion in R&D and clinical trials, as well as VNĐ2 trillion in tech transfer and contract manufacturing of some of key non-communicable disease medicines in the next few years.

Phillip Alexander Wray, director of DKSH Pharma Việt Nam, is also committed to being a trusted partner to the Vietnamese Government and contributing toward the sustainable healthcare development of Việt Nam.

“Joining the health ministry’s effort to realise the digital transformation plan 2025-2030, DKSH can offer support in digitising the patient engagement experience with a paperless process via our PSPhere solution, which has already been launched in many markets," said Wray.

"PSPhere is the digital solution that connects all stakeholders involved in delivering healthcare to patients while ensuring patients are at the centre of the experience. This means that beyond-the-pill services, such as home nursing, remote monitoring devices, digital therapeutics and telemedicine services can be delivered in an integrated manner, and patients can get the support required outside of a clinical setting.”

According to Fitch Solutions, healthcare spending in Việt Nam is expected to reach $23 billion by 2022, while BMI Research's report also shows that the pharmaceutical industry can reach $16.1 billion in size by 2026.

 

Source: VNN

Tags: